In reply [4]

Journal of Clinical Oncology

Volumn 23, Issue 36, 2005, Pages 9429-9432

  Glasmacher, Axel ^a   Prentice, Archibald ^a   Gorschlüter, Marcus ^a   Engelhart, Steffen ^a   Hahn, Corinna ^a   Djulbegovic, Benjamin ^a   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; PLACEBO;

ASPERGILLOSIS; CANCER PATIENT; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; HUMAN; HYPOKALEMIA; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; LETTER; MYCOSIS; NAUSEA; PRIORITY JOURNAL; SYSTEMIC MYCOSIS;

EID: 33847026522     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.2390     Document Type: Letter

References (26)

1. Glasmacher A, Prentice AG, Gorschluter M, et al: Itraconazole prevents invasive fungal infections in neutropenic patients treated for haematological malignancies: Evidence from a meta-analysis of 3,597 patients. J Clin Oncol 21:4615-4626, 2003
2. Gotzsche PC, Johansen HK: Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 314:1238-1244, 1997
3. Gotzsche PC, Johansen HK: Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev CD000026, 2002
4. Pizzo PA, Robichaud KJ, Gill FA, et al: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72:101-111, 1982
5. EORTC International Antimicrobial Therapy Cooperative Group: Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 86:668-672, 1989
6. Goldstone AH, O'Driscoll A: Early AmBisome in febrile neutropenia in patients with haematological disorders. Bone Marrow Transplant 14:15-17, 1994
7. Fukuda M, Hirashima K, Kurane R, et al: Empiric therapy with fluconazole in granulocytopenic patients with carcinoma or leukemia. Jpn J Antibiot 47:1065-1070, 1994
8. Suda T, Omine M, Tsuchiya J, et al: A co-operative study on prophylaxis of fungal infection in patients with hematological diseases: Prophylactic effect of oral administration of amphotericin B (author's transl). Rinsho Ketsueki 21:195-199, 1980
9. Boogaerts M, Winston DJ, Bow EJ, et al: Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135:412-422, 2001
10. Ehninger G, Schuler U, Bammer S, et al: Intravenous itraconazole followed by oral itraconazole versus intravenous amphotericin B as empirical antifungal therapy for febrile neutropenic haematological cancer patients. Blood 100:42b, 2002 (suppl 2; abstr 3631)
11. Glasmacher A, Boogaerts M, Schuler U, et al: Combined analysis of two randomized, controlled trials comparing empirical antimycotic therapy with intravenous itraconazole or amphotericin B in neutropenic patients with persistent fever. Proc Intersc Conf Antimicrob Agents Chemother 413:2004 (abstr M-1016)
12. Prentice AG, Bradford GR: Prophylaxis of fungal infections with itraconazole during remission-induction therapy. Mycoses 32:96-102, 1989 (suppl 1)
13. Morgenstern GR, Prentice AG, Prentice HG, et al: A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies: U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 105:901-911, 1999
14. Kanda Y, Yamamoto R, Chizuka A, et al: Prophylactic action of oral fluconazole against fungal infection in neutropenic patients: A meta-analysis of 16 randomized, controlled trials. Cancer 89:1611-1625, 2000
15. Prentice AG, Warnock DW, Johnson SA, et al: Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J Antimicrob Chemother 36:657-663, 1995
16. Prentice AG, Warnock DW, Johnson SA, et al: Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 34:247-252, 1994
17. Bradford CR, Prentice AG, Warnock DW, et al: Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute rnyeloblastic leukaemia. J Antimicrob Chemother 28:555-560, 1991
18. Viscoli C, Paesmans M, Sanz M, et al: Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients. Clin Infect Dis 32:1532-1537, 2001
19. Glasmacher A, Comely O, Ullmann AJ, et al: An open-label randomised trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. Journal of Antimicrobial Chemotherapy 2006, in press
20. Viscoli C, Paesmans M: Antifungal prophylaxis and the rate of bacteremia among neutropenic patients. Clin Infect Dis 34:289-291, 2002
21. Wenzel RP, Gennings C, Edmond MB: Antifungal antibiotics and breakthrough bacteremias. Clin Infect Dis 32:1538-1539, 2001
22. Huijgens PC, Simoons-Smit AM, van Loenen AC, et al: Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol 52:376-380, 1999
23. Menichetti F, Del Favero A, Martino P, et al: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 28:250-255, 1999
24. Lin SJ, Schranz J, Teutsch SM: Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis 32:358-366, 2001
25. Marr KA, Seidel K, Slavin MA, et al: Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial. Blood 96:2055-2061, 2000
26. Lexchin J, Bero LA, Djulbegovic B, et al: Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ 326:1167-1170, 2003